After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Yahoo Finance discussed the stock recently as it posted Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
As a NASDAQ listed company, MYGN falls under the Healthcare sector while operating within the Diagnostics & Research industry segment. The current market capitalization of Myriad Genetics, Inc. is $2.00B. A total of 0.7 million shares were traded on the day, compared to an average of 647.08K shares.
In the most recent transaction, Riggsbee Richard Bryan sold 30,000 shares of MYGN for 19.09 per share on Dec 01 ’23. After the transaction, the Chief Financial Officer now owns 291,812 company shares. In a previous transaction on Nov 01 ’23, Riggsbee Richard Bryan sold 30,000 shares at 15.69 per share. MYGN shares that Chief Financial Officer owns now total 321,812.
Among the insiders who sold shares, SPIEGELMAN DANIEL K disposed of 8,638 shares on Jun 02 ’23 at a per-share price of $23.01. This resulted in the Director holding 40,493 shares of MYGN after the transaction. In another insider transaction, Lambert Nicole sold 6,433 shares at $23.48 per share on Mar 27 ’23. Company shares held by the Chief Operating Officer now total 240,506.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, MYGN has a high of $24.21 and a low of $13.82.
As of this writing, MYGN has an earnings estimate of -$0.1 per share for the current quarter. EPS was calculated based on a consensus of 12 estimates, with a high estimate of -$0.03 per share and a lower estimate of -$0.18. The company reported an EPS of -$0.03 in the last quarter, which was 62.50% higher than expectations of -$0.08.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. MYGN’s latest balance sheet shows that the firm has $338.80M in Cash & Short Term Investments as of fiscal 2021. There were $92.30M in debt and $204.30M in liabilities at the time. Its Book Value Per Share was $8.71, while its Total Shareholder’s Equity was $967.80M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for MYGN is Buy with a score of 3.36.
